Cargando…

The PI3K/Akt/mTOR pathway: A potential pharmacological target in COVID-19

Coronavirus disease 2019 (COVID-19) has emerged as a serious threat to global health. The disregulation of the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) cell signaling pathway observed in patients with COVID-19 has attracted attention for the possib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Basile, Maria Sofia, Cavalli, Eugenio, McCubrey, James, Hernández-Bello, Jorge, Muñoz-Valle, José Francisco, Fagone, Paolo, Nicoletti, Ferdinando
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Post-Screen (Grey)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8574122/ https://www.ncbi.nlm.nih.gov/pubmed/34763066 http://dx.doi.org/10.1016/j.drudis.2021.11.002

Ejemplares similares

Diabetes, inflammation, and the adiponectin paradox: Therapeutic targets in SARS-CoV-2
por: Ho, Gilbert, et al.
Publicado: (2021)

Myotonic dystrophy type 1 drug development: A pipeline toward the market
por: Pascual-Gilabert, Marta, et al.
Publicado: (2021)

Integrating heterogeneous data to facilitate COVID-19 drug repurposing
por: Prieto Santamaría, Lucía, et al.
Publicado: (2022)

Drug repurposing against SARS-CoV-2 using computational approaches
por: Kumar, Sumit, et al.
Publicado: (2022)

Nucleosides and emerging viruses: A new story
por: Roy, Vincent, et al.
Publicado: (2022)

Efficacy of repurposed antiviral drugs: Lessons from COVID-19
por: Martinez, Miguel Angel
Publicado: (2022)

Repurposing drugs as COVID-19 therapies: A toxicity evaluation
por: Ngan, Deborah K., et al.
Publicado: (2022)

Recent progress on rapid SARS-CoV-2/COVID-19 detection by CRISPR-Cas13-based platforms
por: Aquino-Jarquin, Guillermo
Publicado: (2021)

High‐throughput screening assays for SARS‐CoV‐2 drug development: Current status and future directions
por: Xu, Tuan, et al.
Publicado: (2021)

Drug combination therapy for emerging viral diseases
por: Shyr, Zeenat A., et al.
Publicado: (2021)

Exploiting protease activation for therapy
por: Bleuez, Chloe, et al.
Publicado: (2022)

The current status of COVID-19 vaccines. A scoping review
por: Rueda-Fernández, Manuel, et al.
Publicado: (2022)

Nanosponges: An overlooked promising strategy to combat SARS-CoV-2
por: Mostafavi, Ebrahim, et al.
Publicado: (2022)

Selection of data sets for FAIRification in drug discovery and development: Which, why, and how?
por: Alharbi, Ebtisam, et al.
Publicado: (2022)

How to build a tumor: An industry perspective
por: Schueler, Julia, et al.
Publicado: (2022)

Preclinical evaluation of the PI3K/Akt/mTOR pathway in animal models of multiple sclerosis
por: Mammana, Santa, et al.
Publicado: (2018)

COVID-19 and fibrosis: Mechanisms, clinical relevance, and future perspectives
por: Saifi, Mohd Aslam, et al.
Publicado: (2022)

Nanomedicine approaches to reduce cytokine storms in severe infections
por: Ahmar Rauf, Mohd, et al.
Publicado: (2022)

Impact of COVID-19 on male urogenital health: Success of vaccines
por: Kucukyildiz, Kutay, et al.
Publicado: (2022)

Steps toward nebulization in-use studies to understand the stability of new biological entities
por: Montefusco-Pereira, Carlos Victor
Publicado: (2023)

Harnessing aptamers against COVID-19: A therapeutic strategy
por: Mahmoudi, Ali, et al.
Publicado: (2023)

Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response
por: McCubrey, James A., et al.
Publicado: (2012)

Involvement of Akt-1 and mTOR in Sensitivity of Breast Cancer to Targeted Therapy
por: Sokolosky, Melissa L., et al.
Publicado: (2011)

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging
por: Steelman, Linda S., et al.
Publicado: (2011)

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
por: Chappell, William H., et al.
Publicado: (2011)

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance
por: McCubrey, James A., et al.
Publicado: (2012)

The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients
por: Martelli, Alberto M., et al.
Publicado: (2010)

Computational Modeling of PI3K/AKT and MAPK Signaling Pathways in Melanoma Cancer
por: Pappalardo, Francesco, et al.
Publicado: (2016)

Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels
por: Bressanin, Daniela, et al.
Publicado: (2012)

Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update
por: Evangelisti, Camilla, et al.
Publicado: (2018)

Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia
por: Simioni, Carolina, et al.
Publicado: (2016)

Healthy CD4(+) T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia
por: Alameen, Ayman A.M., et al.
Publicado: (2016)

Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation
por: Simioni, Carolina, et al.
Publicado: (2014)

Cognitive Decline in Rheumatoid Arthritis: Insight into the Molecular Pathogenetic Mechanisms
por: Basile, Maria Sofia, et al.
Publicado: (2021)

PI3K/AKT/mTOR Pathway in Angiogenesis
por: Karar, Jayashree, et al.
Publicado: (2011)

The Role of Macrophages in Neuroinflammatory and Neurodegenerative Pathways of Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis: Pathogenetic Cellular Effectors and Potential Therapeutic Targets
por: Mammana, Santa, et al.
Publicado: (2018)

The Dichotomic Role of Macrophage Migration Inhibitory Factor in Neurodegeneration
por: Basile, Maria Sofia, et al.
Publicado: (2020)

Targeting PI3K/Akt/mTOR Signaling in Cancer
por: Porta, Camillo, et al.
Publicado: (2014)

PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015)

Delineating the genetic heterogeneity of ALS using targeted high-throughput sequencing
por: Kenna, Kevin P, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_54n77dritain62ed9asqeqe6qc